Kintara Therapeutics effects 1-for-50 reverse stock split, trading on adjusted basis Nov 14

TuHURA Biosciences, Inc./NV

Reverse stock split at 1:50 ratio effective 5:00 p.m. ET on November 11, 2022.
No fractional shares issued; any fractional shares rounded up to nearest whole share.
Common stock continues trading on Nasdaq under ticker KTRA, new CUSIP 49720K200.
Authorized shares of common stock reduced proportionally from 50 to 1.
Board approved the split on October 28, 2022; no stockholder vote required under Nevada law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TuHURA Biosciences, Inc./NV: Effected a one-for-fifty (1:50) reverse stock split of common stock and corresponding reduction in authorized shares via Certificate of Change to Articles of Incorporation (effective 2022-11-11).

Change: charter amendment
Effective: 2022-11-11

Exact text from the filing

On November 10, 2022, Kintara Therapeutics, Inc. (the “Company”) filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of Nevada (the “Certificate of Change”), which effected, at 5:00 p.m. Eastern Time on November 11, 2022, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of both the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”) and authorized shares of Common Stock.

View on SEC.gov

23 governance changes filed in the last 30 days. Browse all governance changes →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-22-024708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.